Related references
Note: Only part of the references are listed.Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial
Gianluca Masi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer
Tsuyoshi Konishi et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial
Akihiro Tomida et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study
Kiyoshi Maeda et al.
ANTICANCER RESEARCH (2018)
The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis
Xi Zhong et al.
CANCER MEDICINE (2018)
Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
Xin Yu et al.
CANCER COMMUNICATIONS (2018)
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
R. Glynne-Jones et al.
HELIYON (2018)
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
Jin-Tung Liang et al.
ONCOTARGET (2017)
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
Suguru Hasegawa et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
Margarita Garcia et al.
BMC CANCER (2015)
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
Ramon Salazar et al.
BMC CANCER (2015)
Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial
Jian Xiao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204
Jerome C. Landry et al.
ONCOLOGIST (2015)
Phase II Study of Preoperative Concurrent Chemoradiotherapy with S-1 plus Bevacizumab for Locally Advanced Resectable Rectal Adenocarcinoma
Sotaro Sadahiro et al.
ONCOLOGY (2015)
Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study
C. Borg et al.
ANNALS OF ONCOLOGY (2014)
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
Junichi Hasegawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial
Carlos Fernandez-Martos et al.
ONCOLOGIST (2014)
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
Chia-Chun Wang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Neoadjuvant Oxaliplatin and Capecitabine and Bevacizumab without Radiotherapy for Poor-risk Rectal Cancer: N-SOG 03 Phase II Trial
Keisuke Uehara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
Kathrin Dellas et al.
RADIATION ONCOLOGY (2013)
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
Giampietro Gasparini et al.
ANGIOGENESIS (2012)
Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
David R. Spigel et al.
CLINICAL COLORECTAL CANCER (2012)
NEOADJUVANT BEVACIZUMAB, OXALIPLATIN, 5-FLUOROURACIL, AND RADIATION FOR RECTAL CANCER
Tom Dipetrillo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
BEVACIZUMAB, CAPECITABINE, AMIFOSTINE, AND PREOPERATIVE HYPOFRACTIONATED ACCELERATED RADIOTHERAPY (HYPOARC) FOR RECTAL CANCER: A PHASE II STUDY
Michael I. Koukourakis et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging-Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study
Miguel Nogue et al.
ONCOLOGIST (2011)
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
Vaneja Velenik et al.
RADIATION ONCOLOGY (2011)
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
PHASE II TRIAL OF NEOADJUVANT BEVACIZUMAB, CAPECITABINE, AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER
Christopher H. Crane et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas et al.
LANCET ONCOLOGY (2010)
A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer
Christopher G. Willett et al.
ONCOLOGIST (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer
I. Craven et al.
BRITISH JOURNAL OF CANCER (2007)
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
Christopher G. Willett et al.
SEMINARS IN ONCOLOGY (2006)
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:: Results of FFCD 9203
Jean-Pierre Gerard et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chemotherapy with preoperative radiotherapy in rectal cancer
Jean-Francois Bosset et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results - EORTC 22921
JF Bosset et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative versus postoperative chemoradiotherapy for rectal cancer
R Sauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
